Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients

The International Journal of Neuropsychopharmacology
R LøvlieVidar M Steen

Abstract

This study was undertaken to re-examine whether homozygosity for the Gly-9 variant (allele 2) of the dopamine D3 receptor gene (DRD3) is associated with increased risk for tardive dyskinesia (TD) in schizophrenic patients. Seventy-one antipsychotic-treated subjects with schizophrenia from Newcastle upon Tyne, UK, were genotyped for the presence of allele 1 (Ser-9) and allele 2 (Gly-9) of the dopamine D3 receptor (DRD3) Ser-9-Gly polymorphism. Among 32 patients with TD, 7 subjects (22 %) were homozygous for the Gly-9 variant (2-2 genotype), whereas 4 out of 39 patients (10 %) without TD had this genotype. The non-significant tendency in this sample towards an over-representation of allele 2 and the 2-2 genotype among schizophrenic patients with TD is in line with our initial report as well as recent studies by others, indicating that the Gly-9 allele of DRD3 may be a susceptibility factor for the development of TD in neuroleptic-treated individuals with schizophrenia. There are, however, some recent non-supportive reports, and since the trend in our present study failed to reach statistical significance, further studies on larger samples and future meta-analysis may be necessary to establish the role of the DRD3 in the pathogene...Continue Reading

Citations

Mar 23, 2002·European Journal of Pharmacology·Alessandro SerrettiEnrico Smeraldi
Jun 6, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Osamu OhmoriJun Nakamura
Aug 3, 2011·The Pharmacogenomics Journal·L GreenbaumB Lerer
Dec 12, 2001·British Journal of Clinical Pharmacology·A K Daly, C P Day
Dec 18, 2010·Expert Opinion on Drug Metabolism & Toxicology·Jian-Ping Zhang, Anil K Malhotra
Jan 15, 2011·Trends in Pharmacological Sciences·Stefan LöberPeter Gmeiner
Sep 14, 2010·Clinics in Laboratory Medicine·Peter P Zandi, Jennifer T Judy
Sep 14, 2010·Clinics in Laboratory Medicine·Adriana FosterPeter Buckley
Feb 18, 2010·The Psychiatric Clinics of North America·Peter P Zandi, Jennifer T Judy
Aug 28, 2007·The Psychiatric Clinics of North America·Adriana FosterPeter F Buckley
Apr 10, 2009·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Huei-Ting TsaiCharles Poole
Sep 9, 2006·The International Journal of Neuropsychopharmacology·Clement C ZaiJames L Kennedy
Feb 17, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Clement C ZaiJames L Kennedy
Mar 26, 2004·The Pharmacogenomics Journal·D J MüllerJ L Kennedy
Jan 13, 2006·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Mary Ann RichardsonRaymond F Suckow
Feb 28, 2003·Psychiatric Genetics·Erik G JönssonGöran C Sedvall

❮ Previous
Next ❯

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here